Autopsy report · NCT03893019

MB-CART20.1 Melanoma

“The risk-benefit assessment was not as expected.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 11 months before it stopped.
• 9 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Early Phase 1

Sponsor

Miltenyi Biomedicine GmbH

Sponsor type

Industry

Conditions

Melanoma (Skin)

Interventions

MB-CART20.1

Participants

9

Sites

1

Countries

Germany

Trials that died the same way

• A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
  “The benefit-risk profile no longer supports continuing the study” (62% match in meaning)
• High Flow Oxygen in Patients Undergoing Suspension Laryngoscopy Under General Anesthesia
  “Risk-benefit analysis” (60% match in meaning)
• Study of ART0380 in Patients With Biologically Selected Solid Tumors
  “Sponsor decision, not for reasons affecting the benefit-risk balance.” (58% match in meaning)
• A Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients (MK-5592-105)
  “Study terminated due to an unfavorable risk-benefit analysis” (57% match in meaning)
• A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis
  “Adverse change in the risk/benefit” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.